{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T04:31:08Z","timestamp":1768883468261,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,1]]},"DOI":"10.7759\/cureus.55317","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T11:23:56Z","timestamp":1709292236000},"source":"Crossref","is-referenced-by-count":2,"title":["Improved Side Effect Profile of Alternate-Day Dosing of Lenalidomide"],"prefix":"10.7759","author":[{"given":"Ridwan A","family":"Lawal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oluwole","family":"Banjoko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chukwunonso","family":"Ndulue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sodiq T","family":"Adebeshin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arsalan","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osasumwen E","family":"Ighodaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahman","family":"Olusoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bilikisu","family":"Odusanya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia s","family":"El-Hamdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910232","article-title":"Molecular targeted therapy and immunotherapy for myelodysplastic syndrome","volume":"22","author":"Lee P","year":"2021","unstructured":"Lee P, Yim R, Yung Y, Chu HT, Yip PK, Gill H. Molecular targeted therapy and immunotherapy for myelodysplastic syndrome. Int J Mol Sci. 2021, 22:10232. 10.3390\/ijms221910232","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-022-00402-5","article-title":"Myelodysplastic syndromes","volume":"8","author":"Li H","year":"2022","unstructured":"Li H, Hu F, Gale RP, Sekeres MA, Liang Y. Myelodysplastic syndromes. Nat Rev Dis Primers. 2022, 8:74. 10.1038\/s41572-022-00402-5","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-022-00965-1","article-title":"New approaches to myelodysplastic syndrome treatment","volume":"23","author":"Bazinet A","year":"2022","unstructured":"Bazinet A, Bravo GM. New approaches to myelodysplastic syndrome treatment. Curr Treat Options Oncol. 2022, 23:668-687. 10.1007\/s11864-022-00965-1","journal-title":"Curr Treat Options Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16206","article-title":"How we manage adults with myelodysplastic syndrome","volume":"189","author":"Fenaux P","year":"2020","unstructured":"Fenaux P, Platzbecker U, Ades L. How we manage adults with myelodysplastic syndrome. Br J Haematol. 2020, 189:1016-1027. 10.1111\/bjh.16206","journal-title":"Br J Haematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-844696","article-title":"Treatment of MDS","volume":"133","author":"Platzbecker U","year":"2019","unstructured":"Platzbecker U. Treatment of MDS. Blood. 2019, 133:1096-1107. 10.1182\/blood-2018-10-844696","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.06.005","article-title":"Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes","volume":"33","author":"Tamburini J","year":"2009","unstructured":"Tamburini J, Elie C, Park S, et al.. Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes. Leuk Res. 2009, 33:547-550. 10.1016\/j.leukres.2008.06.005","journal-title":"Leuk Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.9.2943","article-title":"Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy","volume":"96","author":"Hideshima T","year":"2000","unstructured":"Hideshima T, Chauhan D, Shima Y, et al.. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000, 96:2943-2950. 10.1182\/blood.V96.9.2943","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2007.11.037","article-title":"Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide","volume":"32","author":"Kelaidi C","year":"2008","unstructured":"Kelaidi C, Park S, Brechignac S, et al.. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. Leuk Res. 2008, 32:1049-1053. 10.1016\/j.leukres.2007.11.037","journal-title":"Leuk Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2174\/187152012800617678","article-title":"The role of Cdc25A in the regulation of cell proliferation and apoptosis","volume":"12","author":"Shen T","year":"2012","unstructured":"Shen T, Huang S. The role of Cdc25A in the regulation of cell proliferation and apoptosis. Anticancer Agents Med Chem. 2012, 12:631-639. 10.2174\/187152012800617678","journal-title":"Anticancer Agents Med Chem"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0610477104","article-title":"Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients","volume":"104","author":"Pellagatti A","year":"2007","unstructured":"Pellagatti A, J\u00e4dersten M, Forsblom AM, et al.. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A. 2007, 104:11406-11411. 10.1073\/pnas.0610477104","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e328016847a","article-title":"The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes","volume":"14","author":"Melchert M","year":"2007","unstructured":"Melchert M, Kale V, List A. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes. Curr Opin Hematol. 2007, 14:123-129. 10.1097\/MOH.0b013e328016847a","journal-title":"Curr Opin Hematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13653","article-title":"The SPARC protein: an overview of its role in lung cancer and pulmonary fibrosis and its potential role in chronic airways disease","volume":"174","author":"Wong SL","year":"2017","unstructured":"Wong SL, Sukkar MB. The SPARC protein: an overview of its role in lung cancer and pulmonary fibrosis and its potential role in chronic airways disease. Br J Pharmacol. 2017, 174:3-14. 10.1111\/bph.13653","journal-title":"Br J Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165948","article-title":"Efficacy and safety of lenalidomide for treatment of low-\/intermediate-1-risk myelodysplastic syndromes with or without 5q deletion: a systematic review and meta-analysis","volume":"11","author":"Lian XY","year":"2016","unstructured":"Lian XY, Zhang ZH, Deng ZQ, et al.. Efficacy and safety of lenalidomide for treatment of low-\/intermediate-1-risk myelodysplastic syndromes with or without 5q deletion: a systematic review and meta-analysis. PLoS One. 2016, 11:e0165948. 10.1371\/journal.pone.0165948","journal-title":"PLoS One"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.010876","article-title":"Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion","volume":"95","author":"Ximeri M","year":"2010","unstructured":"Ximeri M, Galanopoulos A, Klaus M, et al.. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion. Haematologica. 2010, 95:406-414. 10.3324\/haematol.2009.010876","journal-title":"Haematologica"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-54490-3_21","article-title":"Lenalidomide","volume":"201","author":"Weisel K","year":"2014","unstructured":"Weisel K, Kanz L. Lenalidomide. Recent Results Cancer Res. 2014, 201:347-357. 10.1007\/978-3-642-54490-3_21","journal-title":"Recent Results Cancer Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e3282f0e12b","article-title":"Immunomodulatory drugs in the treatment of myelodysplastic syndromes","volume":"19","author":"Ortega J","year":"2007","unstructured":"Ortega J, List A. Immunomodulatory drugs in the treatment of myelodysplastic syndromes. Curr Opin Oncol. 2007, 19:656-659. 10.1097\/CCO.0b013e3282f0e12b","journal-title":"Curr Opin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001751","article-title":"Lenalidomide in follicular lymphoma","volume":"135","author":"Flowers CR","year":"2020","unstructured":"Flowers CR, Leonard JP, Fowler NH. Lenalidomide in follicular lymphoma. Blood. 2020, 135:2133-2136. 10.1182\/blood.2019001751","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07971.x","article-title":"Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion","volume":"148","author":"Defina M","year":"2010","unstructured":"Defina M, Rondoni M, Gozzetti A, et al.. Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion. Br J Haematol. 2010, 148:483-484. 10.1111\/j.1365-2141.2009.07971.x","journal-title":"Br J Haematol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2010.02.013","article-title":"Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions","volume":"24","author":"Komrokji RS","year":"2010","unstructured":"Komrokji RS, List AF. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions. Hematol Oncol Clin North Am. 2010, 24:377-388. 10.1016\/j.hoc.2010.02.013","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24102","article-title":"Myelodysplastic syndromes: 2015 update on diagnosis, risk-stratification and management","volume":"90","author":"Garcia-Manero G","year":"2015","unstructured":"Garcia-Manero G. Myelodysplastic syndromes: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015, 90:831-841. 10.1002\/ajh.24102","journal-title":"Am J Hematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/221208-improved-side-effect-profile-of-alternate-day-dosing-of-lenalidomide","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T11:24:00Z","timestamp":1709292240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/221208-improved-side-effect-profile-of-alternate-day-dosing-of-lenalidomide"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.55317","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,1]]}}}